A phase II clinical trial led by Winship Cancer Institute of Emory University showed a combination of Keytruda (pembrolizumab) and Cabometyx (cabozantinib, also known as Cometriq) was well tolerated and benefitted 91% of participating patients with recurrent/metastatic head and neck squamous cell carcinoma.
Black and Hispanic older adults whose annual income is slightly above the federal poverty level are more likely than their white peers to face cost-related barriers to accessing health care and filling medications for chronic conditions, according to new research led by a University of Pittsburgh School of Public Health scientist.
Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to PD-1 checkpoint blockade immunotherapy in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy—CTLA-4 blockade—as well as other factors.
Researchers from New Century Health and Neighborhood Health Plan of Rhode Island presented findings from their efforts to increase adoption of hypofractionation in breast cancer patients at the National Comprehensive Cancer Care Network conference, on March 31.
The American Society of Clinical Oncology has published updated guidelines for the initial management of noncastrate advanced, recurrent, or metastatic prostate cancer.
The number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable intermediate-risk cancers, according to a study published in JAMA Internal Medicine.
A phase II study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy showed that a novel monoclonal antibody, known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body.
An international group of researchers led by Children’s Hospital of Philadelphia, Winship Cancer Institute of Emory University, and the New Approaches to Neuroblastoma Therapy Consortium showed that the targeted therapy Lorbrena (lorlatinib) is safe and effective in treating high-risk neuroblastoma.
Results from a clinical trial conducted by researchers at NIH show that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a type of immunotherapy, can live for decades after diagnosis. Lymphomatoid granulomatosis is a rare precancerous condition triggered by Epstein-Barr virus infection. Left untreated, the disease can progress to a high-grade form, which has a poorer prognosis and can quickly turn into an aggressive and fatal B-cell lymphoma.
Researchers from MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer.